Latest News

Significant barriers to care for patients seeking medication for opioid use

Buprenorphine-naloxone (buprenorphine), a highly effective, evidence-based treatment for opioid use disorder (OUD), is difficult to access in states with high rates of death associated with OUD, according to new research led by Harvard T.H. Chan School of Public Health. The study also found that access to buprenorphine is especially challenging among patients with Medicaid coverage.

Source link

Related posts

Disability among India's elderly much higher than census estimates


Cleveland Clinic's first purely laparoscopic living donor surgery for liver transplant


Implementation of electronic patient clinical records in ambulances in the UK: a national survey


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy